ArticleChemistry of materials : a publication of the American Chemical Society2024
Synthetic organic materials for targeting immunotherapies to lymph nodes.
Article in Chemistry of materials : a publication of the American Chemical Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Interventions and platforms that direct lymphangiogenesis to restore physiological homeostasis and enhance immunoregulation.NPJ Regenerative medicine · 2026Review
- Overcoming barriers in primary bone cancer: Nanomaterial-enabled immunotherapy.Materials today. Bio · 2025Review
- Regulation of response to antigen peptides is independent of peptide distribution in lymph node therapeutics.Biomaterials science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Immunotherapies have yielded tremendous advances over the last three decades. However even the most promising therapies, for example monoclonal antibodies, require systemic infusion that can limit dosing and lead to off target immunotoxicity. To address such challenges and improve immunotherapy, the field is investing in synthetic biomaterials to target lymph nodes (LNs) - sites of coordinated immune activation and suppression. These synthetic materials allow enhanced targeting, retention, and control over the signals that are required to elicit desired immune processes during immunotherapy. Two broad classes of materials that have been employed for LN targeting include synthetic lipids and polymers. This review will discuss how the chemistries of these materials can be leveraged to improve lymph node targeting of immunotherapies to treat disease. We will also provide commentary on translational barriers to the clinic, an outlook on current therapies that are clinically used, and a forward-looking perspective.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.